Unsupervised Latent Stain Adaption for Digital Pathology
Authors:
Daniel Reisenbüchler,
Lucas Luttner,
Nadine S. Schaadt,
Friedrich Feuerhake,
Dorit Merhof
Abstract:
In digital pathology, deep learning (DL) models for tasks such as segmentation or tissue classification are known to suffer from domain shifts due to different staining techniques. Stain adaptation aims to reduce the generalization error between different stains by training a model on source stains that generalizes to target stains. Despite the abundance of target stain data, a key challenge is th…
▽ More
In digital pathology, deep learning (DL) models for tasks such as segmentation or tissue classification are known to suffer from domain shifts due to different staining techniques. Stain adaptation aims to reduce the generalization error between different stains by training a model on source stains that generalizes to target stains. Despite the abundance of target stain data, a key challenge is the lack of annotations. To address this, we propose a joint training between artificially labeled and unlabeled data including all available stained images called Unsupervised Latent Stain Adaption (ULSA). Our method uses stain translation to enrich labeled source images with synthetic target images in order to increase supervised signals. Moreover, we leverage unlabeled target stain images using stain-invariant feature consistency learning. With ULSA we present a semi-supervised strategy for efficient stain adaption without access to annotated target stain data. Remarkably, ULSA is task agnostic in patch-level analysis for whole slide images (WSIs). Through extensive evaluation on external datasets, we demonstrate that ULSA achieves state-of-the-art (SOTA) performance in kidney tissue segmentation and breast cancer classification across a spectrum of staining variations. Our findings suggest that ULSA is an important framework towards stain adaption in digital pathology.
△ Less
Submitted 27 June, 2024;
originally announced June 2024.
Applications of artificial intelligence in the analysis of histopathology images of gliomas: a review
Authors:
Jan-Philipp Redlich,
Friedrich Feuerhake,
Joachim Weis,
Nadine S. Schaadt,
Sarah Teuber-Hanselmann,
Christoph Buck,
Sabine Luttmann,
Andrea Eberle,
Stefan Nikolin,
Arno Appenzeller,
Andreas Portmann,
André Homeyer
Abstract:
In recent years, the diagnosis of gliomas has become increasingly complex. Analysis of glioma histopathology images using artificial intelligence (AI) offers new opportunities to support diagnosis and outcome prediction. To give an overview of the current state of research, this review examines 70 publicly available research studies that have proposed AI-based methods for whole-slide histopatholog…
▽ More
In recent years, the diagnosis of gliomas has become increasingly complex. Analysis of glioma histopathology images using artificial intelligence (AI) offers new opportunities to support diagnosis and outcome prediction. To give an overview of the current state of research, this review examines 70 publicly available research studies that have proposed AI-based methods for whole-slide histopathology images of human gliomas, covering the diagnostic tasks of subty** (16/70), grading (23/70), molecular marker prediction (13/70), and survival prediction (27/70). All studies were reviewed with regard to methodological aspects as well as clinical applicability. It was found that the focus of current research is the assessment of hematoxylin and eosin-stained tissue sections of adult-type diffuse gliomas. The majority of studies (49/70) are based on the publicly available glioblastoma and low-grade glioma datasets from The Cancer Genome Atlas (TCGA) and only a few studies employed other datasets in isolation (10/70) or in addition to the TCGA datasets (11/70). Current approaches mostly rely on convolutional neural networks (53/70) for analyzing tissue at 20x magnification (30/70). A new field of research is the integration of clinical data, omics data, or magnetic resonance imaging (27/70). So far, AI-based methods have achieved promising results, but are not yet used in real clinical settings. Future work should focus on the independent validation of methods on larger, multi-site datasets with high-quality and up-to-date clinical and molecular pathology annotations to demonstrate routine applicability.
△ Less
Submitted 5 February, 2024; v1 submitted 26 January, 2024;
originally announced January 2024.